摘要
目的:分析小儿支气管哮喘应用布地奈德雾化吸入联合孟鲁司特钠治疗的临床应用价值。方法:选取2017年6月-2018年6月笔者所在医院儿科门诊接收的86例小儿支气管哮喘患儿为研究对象,电脑编号将患儿随机分为甲组患儿(43例,应用布地奈德雾化吸入治疗)、乙组患儿(43例,应用布地奈德雾化吸入+孟鲁司特钠联合治疗),比较两组患儿临床疗效及不良反应发生率。结果:治疗后乙组患儿总有效率93.02%,比甲组的74.42%高,差异有统计学意义(P<0.05);甲组不良反应发生率6.98%,与乙组的4.65%比较,差异无统计学意义(P>0.05)。结论:小儿支气管哮喘应用布地奈德雾化吸入联合孟鲁司特钠治疗,患儿症状、体征均明显好转,疗效明显,未增加不良反应,具有较高的临床应用价值。
Objective:To analyze the clinical value of Budesonide aerosol inhalation combined with Montelukast Sodium in the treatment of bronchial asthma in children.Method:A total of 86 children with bronchial asthma received from the pediatric clinic of our hospital from June 2017 to June 2018 were selected as the research objects.The children were randomly divided into group A(43 cases were treated with Budesonide aerosol inhalation)and group B(43 cases were treated with Budesonide aerosol inhalation plus Montelukast Sodium)by computer number.The clinical efficacy and incidence of adverse reactions of the two groups were compared.Result:After treatment,the total effective rate of group B was 93.02%,higher than 74.42%of group A,the difference was statistically significant(P<0.05).The incidence of adverse reactions in group A was 6.98%,and which in group B was 4.65%,there was no significant difference between groups(P>0.05).Conclusion:Budesonide aerosol inhalation plus Montelukast Sodium treatment in children with bronchial asthma can significantly improve the symptoms and signs.The curative effect is obvious,and there is no increase in the incidence of adverse reactions.It has high clinical application value.
作者
许建章
关素琴
郑津津
XU Jianzhang;GUAN Suqin;ZHENG Jinjin(Putian Children’s Hospital,Putian 351100,China)
出处
《中外医学研究》
2019年第26期145-147,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
布地奈德雾化吸入
孟鲁司特钠
小儿支气管哮喘
不良反应
Budesonide aerosol inhalation
Montelukast Sodium
Bronchial asthma in children
Adverse reactions
